On October 9, XTALPI fell 5.04% in regular trading, trading at HK$6.785, with turnover of HK$279 million. On the news front, the innovation drug sector collectively pulled back after the holiday, with Hong Kong-listed life sciences tools and AI pharmaceutical stocks broadly weakening, triggering sector-wide linkage effects.
Within the sector, WUXI BIO fell 3.05%, WUXI APPTEC fell 3.45%, GENSCRIPT BIO fell 2.26%, INSILICO fell 2.36%, and WUXI XDC fell 3.53%. The sector had experienced consecutive gains, prompting concentrated profit-taking, while overseas biotech risk appetite declined, pulling capital away from high-valuation innovation drug names. As a core AI pharmaceutical beneficiary, XTALPI was dragged down accordingly.
XTALPI Holdings Limited is a company principally engaged in providing drug and materials science research and development solutions and services for the pharmaceutical and materials science industries.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)